RE:Wow! Great for the sector CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth
Cybin to host conference call today, December 7, 2020, at 5:00 p.m. ET
- Transaction adds extensive intellectual property portfolio and product pipeline to potentially diversify Cybin’s programs and includes multiple additional indications.
- Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens supported by six patent applications.
- Adelia contributes an expanding library of psychedelic derivative drug development candidates with the first lead compounds anticipated to enter clinical studies in 2021.
- Cybin gains access to new patented active pharmaceutical ingredients (APIs) obtained by way of selective modification of the parent molecules (replacing selective hydrogens with deuterium atoms) to alter their pharmacokinetics without modifying therapeutic potential.
- Cybin gains a proprietary drug delivery platform developed by Adelia for the controlled administration of psychedelic therapies bypassing liver metabolism.
- Adelia’s leadership team of accomplished drug developers and scientists brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science rooted in prestigious academic affiliations.
- Cybin gains an operating development facility in the epicenter of Boston biotech, which broadens its presence in the United States.
- A transcript of the conference call and a copy of the presentation will be made available on the Company’s website: www.cybin.com and will be archived for 90 days.
[url=https://www.businesswire.com/news/home/20201207005298/en/CYBIN-Signs-Definitive-Agreement-to-Acquire-Adelia-Therapeutics-as-Part-of-its-Commitment-to-Strategic-Growth ]https://www.businesswire.com/news/home/20201207005298/en/CYBIN-Signs-Definitive-Agreement-to-Acquire-Adelia-Therapeutics-as-Part-of-its-Commitment-to-Strategic-Growth [/url]